Actively Recruiting
Medacta International Multi-National Clinical Surveillance of SMS Femoral Stem Implant Long-Term Observational Study in Hip Replacement Patients
Led by Medacta International SA · Updated on 2026-10-13
550
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a post-marketing surveillance study to observe the safety and performance of the SMS femoral stem prosthesis. This observational study involves patients with severely painful or disabling hip conditions such as osteoarthritis, traumatic arthritis, developmental dysplasia of the hip, avascular necrosis of the femoral head, and rheumatoid polyarthritis. The study is sponsored by Medacta International SA and aims to monitor long-term outcomes after primary total hip replacement surgeries. Participants will receive the SMS femoral stem implant as part of their routine primary total hip replacement surgery. The study will observe these patients over a 10-year period to evaluate various outcomes including the survivorship of the implant, clinical and radiographic performance, patient satisfaction, quality of life, patterns of bone remodeling, stem migration, and adverse events. Assessments are scheduled at multiple time points such as 6 weeks, 6 months, 1 year, and annually up to 10 years. During the study, participants will be monitored through clinical evaluations, radiographic imaging, and questionnaires to assess satisfaction and quality of life. The study will track the implants performance and any adverse events over the extended follow-up period. This long-term monitoring aims to provide comprehensive data on how well the SMS femoral stem prosthesis functions and its impact on patients hip health and mobility.
CONDITIONS
Brief Title
The Medacta International SMS Post-Marketing Surveillance Study
Research Team
M
Mara Colombo, Eng
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here